MARKET

NUVA

NUVA

Nuvasive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.56
+0.80
+1.43%
Opening 12:14 05/27 EDT
OPEN
56.19
PREV CLOSE
55.76
HIGH
56.72
LOW
55.56
VOLUME
216.62K
TURNOVER
11.00M
52 WEEK HIGH
70.76
52 WEEK LOW
45.45
MARKET CAP
2.94B
P/E (TTM)
-71.8222
1D
5D
1M
3M
1Y
5Y
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks · 1d ago
NuVasive Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q1, NuVasive (NASDAQ:NUVA) earned $19.20 million, a 152.27% increase from the preceding quarter. NuVasive's sales decreased to $290.76 million, a 3.75% change since Q4.
Benzinga · 05/18 14:07
Is NuVasive, Inc. (NASDAQ:NUVA) Trading At A 21% Discount?
How far off is NuVasive, Inc. ( NASDAQ:NUVA ) from its intrinsic value? Using the most recent financial data, we'll...
Simply Wall St. · 05/10 10:48
4 Analysts Have This to Say About NuVasive
Analysts have provided the following ratings for NuVasive (NASDAQ:NUVA) within the last quarter:
Benzinga · 05/06 16:11
--Morgan Stanley Adjusts NuVasive Price Target to $62 From $60, Maintains Equal Weight Rating
MT Newswires · 05/06 13:41
NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up
Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.
Zacks · 05/05 13:41
--RBC Capital Adjusts NuVasive's Price Target to $63 From $60, Maintains Outperform Rating
MT Newswires · 05/05 09:28
--Wells Fargo Adjusts NuVasive's Price Target to $62 From $58, Reiterates Overweight Rating
MT Newswires · 05/05 08:03
More
No Data
Learn about the latest financial forecast of NUVA. Analyze the recent business situations of Nuvasive Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
37.50%Buy
43.75%Hold
6.25%Under-perform
0.00%Sell
Analyst Price Target
The average NUVA stock price target is 64.77 with a high estimate of 80.00 and a low estimate of 55.00.
High80.00
Average64.77
Low55.00
Current 56.56
EPS
Actual
Estimate
0.150.300.450.60
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 416
Institutional Holdings: 57.14M
% Owned: 109.79%
Shares Outstanding: 52.04M
TypeInstitutionsShares
Increased
95
3.43M
New
31
1.42M
Decreased
79
4.12M
Sold Out
34
473.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.39%
Healthcare Equipment & Supplies
+2.35%
Key Executives
Non-Executive Chairman/Independent Director
Daniel Wolterman
Chief Executive Officer/Director
J. Christopher Barry
Chief Financial Officer/Executive Vice President
Matthew Harbaugh
Chief Human Resource Officer/Senior Vice President
Andrew Morton
Executive Vice President
Massimo Calafiore
Senior Vice President/General Counsel/Secretary
Nathaniel Sisitsky
Senior Vice President
Dale Wolf
Independent Director
Vickie Capps
Independent Director
John DeFord
Independent Director
Robert Friel
Independent Director
R. Scott Huennekens
Independent Director
Siddhartha Kadia
Independent Director
Leslie Norwalk
Independent Director
Amy Raimundo
No Data
No Data
About NUVA
NuVasive, Inc. is a developer of specialty spinal implants into a global medical technology company that is delivering integrated solutions for spine surgery. The Company's portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, and intraoperative neuromonitoring technology and service offerings. The Company's surgical access instruments include its Maxcess integrated split-blade retractor system. The Company's neuromonitoring software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support. The Company's Advanced Materials Science portfolio of specialized spinal implants is designed to advance spinal fusion by improving the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone (PEEK).

Webull offers kinds of NuVasive, Inc. stock information, including NASDAQ:NUVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NUVA stock methods without spending real money on the virtual paper trading platform.